Summary
- Profile Type
- Technology offer
- POD Reference
- TOIT20240321012
- Term of Validity
- 21 March 2024 - 21 March 2025
- Company's Country
- Italy
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
-
Italian company developed and double-patented an innovative coating for indoor surfaces which remains active 24/7 for 3 months with a 99.99% efficacy and with a 98% reduction on chemical products’ use, with the aim of preventing HAIs (Healthcare Associated Infections) and AMR (Antimicrobial Resistance). The company seeks to joint a consortium as a partner on HORIZON-JU-GH-EDCTP3-2024-01-04-two-stage ‘Tackling Antimicrobial Resistance (AMR) through R&D in
novel and existing antimicrobials’ call. - Full Description
-
The Italian company is active in the field of microbiology and nanotechnology research for the healthcare sector. Its mission is to bring innovation for human health by preventing microbial infections in an efficient and sustainable way. Its research department liaise with a leading Italian University for microbiology research, other R&D centres and universities in Europe, and an electrostatic technology developer in the USA.
Thanks to its 99.99% antimicrobial residual efficacy 24/7 for 3 months, the solution represents a concrete shift in paradigm preventing bacteria presence in any indoor environment - preventative solution.
The innovation offered meets the needs of the major bacteria-sensitive environments and it is considered an effective risk management procedure in the healthcare sector aimed at reducing the impact of HAIs (Healthcare Associated Infections).
The company is looking for a coordinator with a consortium that is planning to submit a proposal for the Horizon Europe Call under topic HORIZON-JU-GH-EDCTP3-2024-01-04-two-stage ‘Tackling Antimicrobial Resistance (AMR) through R&D in novel and existing antimicrobials'.
Deadline submission first step: April 4, 2024. - Advantages and Innovations
-
Innovation:
The company developed 3 proprietary formulations which, once sequentially applied in indoor spaces, molecularly interact with surfaces and generate an invisible, long lasting, non-leaching antimicrobial coating, covalently bond to surfaces.A valuable innovation in the field of antimicrobial coatings. The coating attracts pathogens by electrostatic action. Its molecular micro spikes puncture the pathogen’s external membrane by physical action and instantly kill them on contact, with no poisoning. This physical action prevents two of the most detrimental issues in healthcare: the development of bacteria resistance to antimicrobials (AMR) – often caused by the continuous and excessive use of biocides, among others - and the biofilm generation over time.
Operational advantages:
The 3 formulations are to be applied through professional electrostatic devices - EPA tested and CE certified - which allow for a 360° surface coverage, with no need to free up spaces. This extremely efficient technology prevents any unwanted dispersion of product in the environment. A 1000sqm room can be treated in just 90’ on average, with only 2lts of product, for a months-long result. Rooms are accessible right after 10’ drying time.
Technical advantages:
Just 4 applications per year for a 24/7 protection. Thanks to its extremely high residual efficacy and extraordinary duration over time, this technology reduces the use of chemicals up to 98% compared to a daily conventional sanitization. Being non-leaching - it remains permanently attached to surfaces -, the coating is completely safe for humans and the environment. Double patented, ECHA and BPR compliant, ISO 22196:2011 certified, active against GN and GP bacteria. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 17: Partnerships to achieve the GoalGoal 3: Good Health and Well-being
Partner Sought
- Expected Role of a Partner
- The company is looking for a coordinator with a consortium that is planning to submit a proposal for the Horizon Europe Call under topic HORIZON-JU-GH-EDCTP3-2024-01-04-two-stage ‘Tackling Antimicrobial Resistance (AMR) through R&D in novel and existing antimicrobials’.
- Type and Size of Partner
- R&D InstitutionUniversitySME 11-49OtherSME 50 - 249SME <=10Big company
- Type of partnership
- Research and development cooperation agreement
Call details
- Coordinator required
-
Yes
Dissemination
- Technology keywords
- 06002008 - Microbiology03004011 - Care, Hygiene, Beauty03004010 - Special chemicals, intermediates06001018 - Virus, Virology/Antibiotics/Bacteriology
- Market keywords
- 05007007 - Other medical/health related (not elsewhere classified)
- Targeted countries
- All countries